Abstract
Head and neck squamous cell carcinoma (HNSCC) is a deadly disease which in many cases is managed with a combination of radiation and chemotherapy. Unfortunately, the ability to monitor treatment response in real time is limited. Thus, truly individualized therapy remains an unrealized goal. We have previously investigated the possibility of combining advanced imaging using magnetic resonance imaging (MRI) combined with the analysis of circulating tumor cells to classify response in HNSCC as part of a prospective trial (PREDICT-HN). An adaption of the methodology from that trial is described herein in hopes of allowing for recapitulation and further development of this exciting methodology.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Siegel RL, Miller KD, Jemal A (2017) Cancer statistics. CA Cancer J Clin 67(1):7–30
Chaturvedi AK, Engels EA, Anderson WF, Gillison ML (2008) Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26(4):612–619
Blomberg M, Nielsen A, Munk C, Kjaer SK (2011) Trends in head and neck cancer incidence in Denmark, 1978-2007: focus on human papillomavirus associated sites. Int J Cancer 129(3):733–741
Auluck A, Hislop G, Bajdik C, Poh C, Zhang L, Rosin M (2010) Trends in oropharyngeal and oral cavity cancer incidence of human papillomavirus (HPV)-related and HPV-unrelated sites in a multicultural population: the British Columbia experience. Cancer 116(11):2635–2644
Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C (2015) Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol 33(29):3235–3242
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24–35
Strojan P, Hutcheson KA, Eisbruch A, Beitler JJ, Langendijk JA, Lee AWM et al (2017) Treatment of late sequelae after radiotherapy for head and neck cancer. Cancer Treat Rev 59:79–92
Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ et al (2019) Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 393(10166):40–50
Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T et al (2019) Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 393(10166):51–60
Skinner HD, Giri U, Yang LP, Kumar M, Liu Y, Story MD et al (2017) Integrative analysis identifies a novel AXL-PI3 Kinase-PD-L1 signaling axis associated with radiation resistance in head and neck cancer. Clin Cancer Res 23(11):2713–2722
Hess J, Unger K, Maihoefer C, Schuttrumpf L, Wintergerst L, Heider T et al (2019) A five-MicroRNA signature predicts survival and disease control of patients with head and neck cancer negative for HPV infection. Clin Cancer Res 25(5):1505–1516
Li J, Wang P, Xu Y (2017) Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: a systematic review and meta-analysis. PLoS One 12(6):e0179536
Liu X, Kumar M, Yang L, Molkentine DP, Valdecanas D, Yu S et al (2018) BAP1 is a novel target in HPV-negative head and neck cancer. Clin Cancer Res 24(3):600–607
Skinner HD, Giri U, Yang L, Woo SH, Story MD, Pickering CR et al (2016) Proteomic profiling identifies PTK2/FAK as a driver of radioresistance in HPV-negative head and neck cancer. Clin Cancer Res 22(18):4643–4650
Neskey DM, Osman AA, Ow TJ, Katsonis P, McDonald T, Hicks SC et al (2015) Evolutionary action score of TP53 identifies high-risk mutations associated with decreased survival and increased distant metastases in head and neck cancer. Cancer Res 75(7):1527–1536
Heukelom J, Fuller CD (2019) Head and neck cancer adaptive radiation therapy (ART): conceptual considerations for the informed clinician. Semin Radiat Oncol 29(3):258–273
Wu XL, Tu Q, Faure G, Gallet P, Kohler C, Bittencourt M de C. (2016) Diagnostic and prognostic value of circulating tumor cells in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Sci Rep 6:20210
Ng SP, Bahig H, Wang J, Cardenas CE, Lucci A, Hall CS et al (2018) Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching ‘liquid biopsy’ and quantitative tumor modeling. BMC Cancer 18(1):903
https://documents.cellsearchctc.com/pdf/e631600001/e631600001_EN.pdf
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Ng, S.P., Fuller, C.D., Skinner, H.D. (2021). Correlation of Circulating Tumor Cell Measurements with 3D Quantitative Tumor Characterization to Predict Clinical Outcomes in Cancer. In: Robles-Flores, M. (eds) Cancer Cell Signaling. Methods in Molecular Biology, vol 2174. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0759-6_9
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0759-6_9
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0758-9
Online ISBN: 978-1-0716-0759-6
eBook Packages: Springer Protocols